Insulet Corporation

PODD Healthcare Medical Devices

Insulet Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 30.7% from fiscal 2024. In the quarter to June 2026, revenue grew 23.5%, EPS grew 328.1%, free cash flow fell 70.5% and total debt fell 32.2%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

141.10 2.33 +1.68%
Market cap
$9.6B
P/E
26.4×
Fwd P/E
24.7×
Dividend yield
—
F-score
6/9
Altman Z
9.09
Beneish M
−2.59
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
0.00 0.00 1,322.00 951.11 2,323.91 1,156.83 4,091.14 70.88 43.66 81.21
Piotroski F-Score
6 5 6 5 5 4 4 6 8 6
P/S ratio
5.83 8.63 8.28 14.05 18.30 16.39 15.22 8.59 8.83 7.38
Altman Z-Score
2.76 3.64 4.03 6.26 8.56 8.18 7.68 6.15 7.40 9.09
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 399.61 61.76 57.15
Altman Z″-Score (non-manufacturers)
(0.33) 0.99 0.55 0.94 3.17 3.30 2.31 3.38 4.29 4.78
Beneish M-Score
(3.23) (1.56) (2.17) (3.07) (2.49) (1.72) (2.18) (1.85) (2.35) (2.59)
P/Operating CF
106.54 182.81 153.38 221.19 973.42 (706.37) 391.87 322.69 124.03 109.09
P/B ratio
33.86 25.25 22.01 136.68 27.42 32.38 41.70 19.91 15.10 13.20
Price to Tangible BV
99.77 35.01 28.80 453.00 30.93 37.53 56.89 25.05 17.23 14.85
EV/Sales
5.98 8.95 8.86 14.75 18.42 16.83 15.78 9.01 9.04 7.47
EV/EBITDA
701.95 638.80 116.18 139.79 155.85 100.84 204.31 52.23 48.04 35.85
EV/Operating CF
138.04 100.54 139.16 110.67 198.33 (271.58) 173.06 104.99 43.52 35.53
EV/FCF
(354.03) (127.76) (38.46) (150.20) (201.94) (96.93) (537.72) 419.10 63.20 57.81
Quick Ratio
5.88 5.74 3.16 2.82 5.02 4.16 2.41 2.36 2.50 1.81
Current Ratio
6.64 6.24 3.99 3.75 6.01 5.81 3.60 3.51 3.58 2.81
Net Debt/EBITDA
10.93 19.40 7.05 6.62 1.04 2.63 7.21 2.43 1.09 0.41
Debt/Assets
72.87% 69.32% 63.75% 78.04% 56.56% 62.18% 62.27% 54.70% 44.69% 29.75%
Debt/Equity
5.27 3.57 2.79 11.75 1.76 2.29 2.94 1.93 1.14 0.63
Asset Turnover
1.00 0.73 0.65 0.71 0.60 0.56 0.61 0.70 0.73 0.86
Operating CF/Net income
(0.55) (1.54) 10.88 8.48 12.35 (4.05) 25.87 0.71 1.03 2.30
Capex/Depreciation
(1.60) (5.55) (10.41) (6.13) (3.01) (2.14) (2.49) (1.50) (1.66) (2.43)
Interest Coverage
(0.74) (0.35) 1.29 1.81 1.14 2.04 1.04 6.08 7.23 7.98
ROE
(59.42%) (24.18%) 1.78% 8.06% 2.00% 2.90% 0.89% 34.12% 43.03% 18.12%
ROA
(7.89%) (4.21%) 0.38% 1.12% 0.45% 0.86% 0.21% 8.53% 14.74% 7.87%
ROIC
(6.87%) (1.62%) 3.32% 5.28% 4.50% 7.58% 1.95% 9.52% 11.79% 16.94%
Return on Tangible Assets
(8.04%) (4.79%) 0.55% 1.39% 0.45% 1.03% 0.30% 11.48% 20.05% 12.03%
Average Days of Receivables
28.65 42.00 49.66 34.27 38.46 53.48 57.49 77.36 64.40 69.67
Research and Development Expense of Revenue
15.18% 16.32% 15.79% 17.92% 16.23% 14.57% 13.81% 12.08% 10.60% 11.12%
Selling, General and Administrative Expense of Revenue
45.25% 45.04% 43.99% 40.37% 42.46% 42.41% 45.03% 43.30% 44.27% 43.02%
Intangible Assets out of Total Assets
0.09 0.05 0.05 0.05 0.04 0.04 0.06 0.06 0.05 0.05
Share Based Compensation of Revenue
6.44% 6.88% 6.65% 3.89% 3.97% 3.13% 3.13% 2.85% 3.35% 2.32%
Graham Net Nets
(0.01) (0.03) (0.05) (0.05) 0.00 (0.01) (0.02) (0.02) 0.00 0.01
Graham Number
0.00 0.00 2.21 2.25 4.80 6.52 3.29 26.41 48.23 41.19
Earnings Yield
(1.37%) (0.67%) 0.08% 0.11% 0.04% 0.09% 0.02% 1.41% 2.29% 1.23%
Free Cash Flow Yield
(0.29%) (0.81%) (2.78%) (0.70%) (0.50%) (1.06%) (0.19%) 0.25% 1.62% 1.75%
Revenue per Share
6.41 8.00 9.58 12.18 13.97 16.23 18.82 24.33 29.56 38.50
Operating CF per Share
0.28 0.71 0.61 1.62 1.30 (1.01) 1.72 2.09 6.14 8.09
Capex per Share
(0.39) (1.33) (2.76) (2.82) (2.57) (1.81) (2.27) (1.57) (1.91) (3.12)
Free Cash Flow per Share
(0.11) (0.62) (2.15) (1.20) (1.27) (2.82) (0.55) 0.52 4.23 4.97
Cash per Share
5.22 7.59 4.91 6.21 14.64 11.69 9.73 10.10 13.61 10.18
Shareholders Equity per Share
1.10 2.73 3.60 1.25 9.32 8.22 6.87 10.50 17.29 21.54
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
1.10 2.73 3.60 1.25 9.32 8.22 6.87 10.50 17.29 21.54
Free Cash Flow
(6.20) (35.90) (126.50) (72.50) (82.50) (190.80) (38.30) 36.50 296.20 349.90
Working Capital
314.26 451.15 345.60 433.30 1,040.90 1,101.00 949.30 1,131.70 1,362.90 1,233.90
Capital Expenditures
(22.11) (77.20) (162.40) (170.90) (166.50) (122.70) (157.30) (109.20) (134.00) (219.40)
Net Current Asset Value
(23.54) (121.06) (255.30) (476.00) (20.60) (162.70) (460.70) (272.60) 15.20 238.80
EV/EBIT
0.00 0.00 187.68 217.79 323.49 146.78 547.73 69.50 60.61 42.69
Capex to Sales
0.06 0.17 0.29 0.23 0.18 0.11 0.12 0.06 0.06 0.08
Price to Operating Income
0.00 0.00 175.39 207.47 321.32 142.96 528.39 66.27 59.23 42.20
Other line items
Depreciation/Fixed assets
0.31 0.13 0.06 0.07 0.12 0.11 0.11 0.11 0.11 0.11
Cash ROIC
(0.89%) (3.08%) (11.57%) (5.39%) (3.16%) (7.28%) (1.50%) 1.28% 8.36% 11.00%
Accounts Receivable Turnover
10.29 11.29 8.67 10.11 10.99 8.57 7.12 6.00 5.71 6.14
Accounts Payable Turnover
10.99 9.93 7.76 6.45 5.93 7.55 14.59 21.49 32.10 16.21
Inventory Turnover
6.56 5.38 3.68 2.99 2.52 1.52 1.54 1.43 1.50 1.74
Average Days of Payables
30.81 47.75 48.08 77.13 61.31 39.69 22.50 13.05 11.55 35.64
Days of Inventory on Hand
83.15 66.10 134.61 142.94 174.85 319.20 253.32 273.55 250.99 215.05
Average Receivables
35.67 41.09 65.04 73.00 82.30 128.15 183.30 282.65 362.60 441.20
Average Payables
14.19 18.79 24.96 40.00 54.30 45.90 34.25 25.00 19.50 47.40
Average Inventory
23.77 34.65 52.60 86.20 127.65 228.75 325.00 374.70 416.50 441.50
Average Assets
365.89 636.70 872.72 1,035.80 1,507.90 1,960.85 2,149.95 2,419.65 2,837.95 3,139.05
Average Common Equity
48.60 110.83 185.31 144.00 339.75 579.95 516.35 604.55 972.15 1,363.45

Fold the line items

Columns are period end dates